Geovax Labs (GOVX)

Dec 9, 2024, 9:00 AM EST - 5 weeks ago

GeoVax Receives Notice of Allowance For Cancer Vaccine Patent

Nov 26, 2024, 9:00 AM EST - 7 weeks ago

GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference

Nov 12, 2024, 11:33 PM EST - 2 months ago

GeoVax Labs, Inc. (GOVX) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:00 PM EST - 2 months ago

GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 5, 2024, 9:00 AM EST - 2 months ago

GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024

Oct 2, 2024, 9:00 AM EDT - 3 months ago

GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Sep 3, 2024, 9:00 AM EDT - 4 months ago

GeoVax to Participate in Upcoming Investor Conferences in September

Aug 28, 2024, 8:59 PM EDT - 5 months ago

GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market

Aug 20, 2024, 8:09 AM EDT - 5 months ago

GeoVax's stock slides 20% after company raises $8.5 million in stock sale

Aug 20, 2024, 7:45 AM EDT - 5 months ago

GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market

Aug 20, 2024, 7:00 AM EDT - 5 months ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CIA CVKD ELUT EUDA GDTC GOSS IMRN

Aug 19, 2024, 7:30 AM EDT - 5 months ago

GeoVax's stock soars 54% to lead rally in companies developing mpox treatments

Aug 15, 2024, 9:00 AM EDT - 5 months ago

GeoVax to Present at the Emerging Growth Conference on August 21, 2024

Aug 15, 2024, 8:36 AM EDT - 5 months ago

Mpox outbreak: 5 stocks to watch out for as the emergency unfolds

EBS SIGA

Aug 10, 2024, 6:15 AM EDT - 5 months ago

GeoVax Labs, Inc. (GOVX) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 9:00 AM EDT - 5 months ago

GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board

Aug 6, 2024, 4:00 PM EDT - 5 months ago

GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 31, 2024, 10:15 AM EDT - 6 months ago

Update: GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review

May 14, 2024, 8:01 PM EDT - 8 months ago

GeoVax Labs, Inc. (GOVX) Q1 2024 Earnings Call Transcript

Apr 4, 2024, 12:30 PM EDT - 10 months ago

GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine

Mar 28, 2024, 9:00 AM EDT - 10 months ago

GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress

Mar 12, 2024, 9:00 AM EDT - 11 months ago

GeoVax to Present at the 36th Annual Roth Conference

Mar 6, 2024, 9:00 AM EST - 11 months ago

GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System

Mar 1, 2024, 2:34 AM EST - 11 months ago

GeoVax Labs, Inc. (GOVX) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 4:00 PM EST - 11 months ago

GeoVax Reports 2023 Year-End Financial Results and Provides Business Update

Feb 22, 2024, 9:00 AM EST - 11 months ago

GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024

Feb 19, 2024, 9:00 AM EST - 11 months ago

GeoVax to Present at the 2024 BIO CEO & Investor Conference

Feb 13, 2024, 9:00 AM EST - 1 year ago

GeoVax Announces Multiple Patent Issuances and Allowances

Feb 6, 2024, 9:00 AM EST - 1 year ago

GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster

Jan 29, 2024, 9:00 AM EST - 1 year ago

GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

Jan 8, 2024, 9:00 AM EST - 1 year ago

GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology

Jan 4, 2024, 9:00 AM EST - 1 year ago

GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients

Jan 3, 2024, 9:00 AM EST - 1 year ago

GeoVax Announces Issuance of Malaria Vaccine Patent

Dec 27, 2023, 9:00 AM EST - 1 year ago

GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024

Dec 19, 2023, 9:00 AM EST - 1 year ago

GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox

Nov 30, 2023, 4:30 PM EST - 1 year ago

GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress

Nov 29, 2023, 9:00 AM EST - 1 year ago

GeoVax to Participate in Upcoming December Investor Events

Nov 28, 2023, 9:00 AM EST - 1 year ago

GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress

Nov 14, 2023, 9:00 AM EST - 1 year ago

Progress on GeoVax's Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023

Nov 8, 2023, 9:26 PM EST - 1 year ago

GeoVax Labs, Inc. (GOVX) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 4:00 PM EST - 1 year ago

GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update

Oct 30, 2023, 9:00 AM EDT - 1 year ago

GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine

Oct 25, 2023, 9:00 AM EDT - 1 year ago

GeoVax to Participate in Upcoming November Investor and Industry Events

Oct 24, 2023, 9:00 AM EDT - 1 year ago

GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities

Oct 9, 2023, 9:00 AM EDT - 1 year ago

GeoVax Receives Notice of Allowance for Marburg Vaccine Patent

Oct 5, 2023, 9:00 AM EDT - 1 year ago

GeoVax Receives Notice of Allowance for HIV Vaccine Patent

Sep 27, 2023, 9:00 AM EDT - 1 year ago

GeoVax to Participate in Upcoming October Investor and Industry Events

Sep 20, 2023, 9:00 AM EDT - 1 year ago

GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference

Sep 19, 2023, 9:00 AM EDT - 1 year ago

GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients

Sep 12, 2023, 9:00 AM EDT - 1 year ago

GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference